Background: Development of biomarkers for autism spectrum disorder (ASD) has still remained a challenge to date. Recently, alterations of the expression of microRNAs (miRNAs) in peripheral blood, serum and post-mortem brain tissue have been linked to ASD. miRNAs are known to be secreted by various cell types and can mediate transmission of information into recipient cells and to modulate their physiological functions. On this basis it is assumed that circulating miRNAs could be useful biomarkers for the diagnosis or prognosis of pathological conditions.
Aim: The aim of this study was to test whether circulating miRNAs display differential expression profile in serum of ASD patients.
Patients and methods: The relative expression levels of 42 miRNAs were analyzed by stem-loop qRT-PCR assay in the serum of ASD patients compared to healthy controls.
Results: The results indicated that 11 miRNAs in ASD patients were substantially higher expressed than these in control subjects, and 29 miRNAs were lower expressed, respectively. In addition, target gene analysis displayed that the altered serum miRNAs targeted some important genes like alpha 1C subunit of voltage-dependent calcium channel, L type, (CACNA1C), beta 1 subunit of voltage-dependent calcium channel (CACNB1) and other genes involved in epigenetic processes like dicer 1, coding ribonuclease type III (DICER).
Conclusion: Our results suggested that differentially expressed miRNAs in serum might be involved in ASD molecular pathways, and serum miR-424-5p, miR-197- 5p, miR-328-3p, miR-500a-5p, miR-619-5p, miR-3135a, miR-664a-3p, and miR- 365a-3p might be able to serve as potential biomarkers for ASD because they displayed significant alterations in the expression profile in children diagnosed with ASD.
1. Holt R, Monaco AP. Links between genetics and pathophysiology in the autism spectrum disorders. EMBO; Mol Med 2011;3(8):438-50.
2. Sarachana T, Zhou R, Chen G, et al. Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profi ling of lymphoblastoid cell lines. Genome Med 2010;2(4):23.
3. Abu-Elneel K, Liu T, Gazzaniga FS, et al. Heterogeneous dysregulation of microRNAs across the autism spectrum. Neurogenetics 2008;9(3):153-61.
4. Talebizadeh Z, Butler MG, Theodoro MF. Feasibility and relevance of examining lymphoblastoid cell lines to study role of microRNAs in autism. Autism Res 2008;1(4):240-50.
5. Friedman RC, Farh KK, Burge CB, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
6. De Tullio G, De Fazio V, Sgherza N, et al. Challenges and opportunities of micro RNAs in lymphomas. Molecules 2014;19:14723-81.
7. Zimmerman AL, Shiyong Wu. MicroRNAs, cancer and cancer stem cells. Cancer Lett 2011; 771(300): 10-9.
8. Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fl uids. Clin Chem 2010;56:1733-41.
9. Kosaka N, Izumi H, Sekine K, et al. MicroRNA as a new immune-regulatory agent in breast milk. Silence 2010;1:7.
10. Scherzer CR, Eklund AC, Morse LJ, et al. Molecular markers of early Parkinson’s disease based on gene expression in blood. Proc Natl Acad Sci USA 2007;104:955-60.
11. Padmos RC, Hillegers MH, Knijff EM, et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of infl ammatory genes in monocytes. Arch Gen Psychiatry 2008;65:395-407.
12. Coppola G, Karydas A, Rademakers R, et al. Gene expression study on peripheral blood identifies progranulin mutations. Ann Neurol 2008;64:92-6.
13. Washizuka S, Iwamoto K, Kakiuchi C, et al. Expression of mitochondrial complex I subunit gene NDUFV2 in the lymphoblastoid cells derived from patients with bipolar disorder and schizophrenia. Neurosci Res 2009;63:199-204.
14. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
15. Lord C, Rutter M, Couteur, AL. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994;24:659-85.
17. Dweep H, Sticht C, Pandey P, et al. miRWalk - database: prediction of possible miRNA binding sites by “walking” the genes of 3 genomes. Journal of Biomedical Informatics 2011;44: 839-47. (available at http://mirwalk.uni-hd.de)
18. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
19. Vasu MM, Anitha A, Thanseem I, et al. Serum microRNA profi les in children with autism. Molecular Autism 2014;5:40.
20. Mor M, Nardone S, Sams DS, et al. Hypomethylation of miR-142 promoter and upregulation of microRNAs that target the oxytocin receptor gene in the autism prefrontal cortex. Mol Autism 2015;6:46.
21. Ander BP, Barger N, Stamova B. Atypical miRNA expression in temporal cortex associated with dysregulation of immune, cell cycle, and other pathways in autism spectrum disorders. Mol Autism 2015;6:37.